ReviewMolecules (Basel, Switzerland)2022
Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Hybrid Chemo-Enzymatic Heterogeneous Catalyst for Green and Enantioselective Hydroxylation.ACS central science · 2026Article
- Heterogeneous Organocatalytic Synthesis of Propargylic Esters Using a Polymer-Supported N-Heterocyclic Carbene.ChemSusChem · 2026Article
- Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods.Chirality · 2026Review
- Supramolecular protecting groups can impart prosthetic stereoselectivity to catalytic systems employing unmodified achiral heterogenous catalysts.Chemical science · 2026Article
- Fatty Acid and Amino Acid Derivatives in Organocatalyzed Michael Additions.Molecules (Basel, Switzerland) · 2026Article
- Heterogeneous organocatalysis: the proline case.RSC advances · 2025Review
- Recent advances in catalytic asymmetric synthesis.Frontiers in chemistry · 2024Review
- A novel recyclable organocatalyst for the gram-scale enantioselective synthesis of (Beilstein journal of organic chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Majority of drugs act by interacting with chiral counterparts, e.g., proteins, and we are, unfortunately, well-aware of how chirality can negatively impact the outcome of a therapeutic regime. The number of chiral, non-racemic drugs on the market is increasing, and it is becoming ever more important to prepare these compounds in a safe, economic, and environmentally sustainable fashion. Asymmetric organocatalysis has a long history, but it began its renaissance era only during the first years of the millennium. Since then, this field has reached an extraordinary level, as confirmed by the awarding of the 2021 Chemistry Nobel Prize. In the present review, we wish to highlight the application of organocatalysis in the synthesis of enantio-enriched molecules that may be of interest to the pharmaceutical industry and the medicinal chemistry community. We aim to discuss the different activation modes observed for organocatalysts, examining, for each of them, the generally accepted mechanisms and the most important and developed reactions, that may be useful to medicinal chemists. For each of these types of organocatalytic activations, select examples from academic and industrial applications will be disclosed during the synthesis of drugs and natural products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.